This table presents computed estimates for age-specific 5-year overall survival (%) in patients with resected colon cancer with/without 5FU-based adjuvant chemotherapy. There is a section for Low grade and a section for High grade.

View Table

A pooled analysis of adjuvant chemotherapy trials for patients with resected colon cancer was performed to quantify the benefit of 5FU-based chemotherapy for predefined clinical and pathologic subgroups. The table below provides individualized estimates of baseline prognosis and adjuvant-therapy benefit based on T stage, nodal status and grade.

View Table

Using the end point of 5-year DFS, the model was evaluated for discriminating ability, calibration and over-fitting. The calibration of the model was assessed by comparing the predicted 5-year DFS rates for surgery alone and for surgery plus adjuvant therapy with the corresponding observed or Kaplan-Meier estimate probabilities.

View Table

Predicting the outcome is important to avoid overtreating some patients with Hodgkin's disease, and to identify others in whom standard treatment is likely to fail.

The International Extranodal Lymphoma Study Group (IELSG) analysed a multicenter retrospective series of immunocompetent patients with PCNSL. A prognostic score resulting from the combined analysis of the independent variables is proposed in the light of its clinical relevance.

View Table